Protagonist Therapeutics, Inc (PTGX) Dividend History

Company News

• Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

  Protagonist Therapeutics and Takeda Pharmaceutical's investigational drug rusfertide met its primary endpoint in a late-stage study for polycythemia vera, a type of blood cancer. The drug showed a significantly higher proportion of clinical responders compared to placebo.

  Benzinga
• BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment

  BESREMi, a FDA-approved treatment for polycythemia vera, is gaining market share due to its potential for better tolerability and lower risk of treatment-related malignancies compared to competitors like ruxolitinib and hydroxyurea.

  GlobeNewswire Inc.

  Featured Companies: ABBV BMY GSKH IONS MRK
• All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy

  Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  Zacks Investment Research
• Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

  Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

  The Motley Fool

  Featured Companies: CVRX JNJ
• A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?

  Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.

  MarketWatch

  Featured Companies: ABBV BMY JNJ LLY PFE